The FDA said last week after Vioxx was withdrawn that the problems were unique to that drug
When Merck voluntarily withdrew Vioxx  FDA officials said heart problems were unique to that drug and that the mechanism underlying them was nt known
Galson said that his agency met often with Merck to discuss earlier troubling Vioxx studies  and said that  we insisted that we needed more information about the cardiovascular risks
Merck officials said last week its latest research showed an increased risk of heart attack and other cardiovascular complications in patients who took Vioxx for at least 18 months FDA urged to weigh in
The FDA safety officer in charge of the report  David Graham  concluded that Vioxx posed much greater cardiovascular risk than the other major drug in its class  Celebrex